DIFFERENTIATED BUSINESS MODEL
Biocon is an innovation-led global biopharmaceutical enterprise that aims to transform scientific discoveries into medical advances that can impact human health. We have built differentiated capabilities based on a deep insight into Life Sciences. We have acquired the knowledge, expertise and skills essential for developing and manufacturing ‘best-in-class’ small and large molecule therapies. We invested ahead of the curve in the promising future of Targeted Biologics that are revolutionizing the treatment of chronic diseases. We have consciously chosen to focus on segments that require intensive R&D efforts and long gestation periods.
Our strategy is aligned to the global imperative of improving access to high-quality, affordable biopharmaceuticals and specialty medicines for Diabetes, Oncology and Immunology. We have leveraged India’s value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed, and quality. This has translated into a diversified and differentiated pipeline of fermentation-derived complex generics, biosimilars that include insulins and monoclonal antibodies, and novel biologics.
We believe our value proposition built around differentiation and scale has enabled us to pursue a patient centric approach aimed at providing access to world-class biopharmaceuticals in pursuit of enabling the ‘Right to health’.
OUR GROWTH VERTICALS
Biocon's four key growth verticals aim to deliver sustainable, long term value for patients, partners and healthcare systems across the globe. The fully integrated business model spans the complete drug value chain, from pre-clinical discovery to clinical development and to commercialisation of small molecule APIs, generic formulations, branded formulations and biologics including both novels & biosimilars.
We have taken a range of novel biologics and biosimilars from ‘lab to market.’
We have built a pipeline of Novel Biologics to address the unmet needs in diseases.
We offer a range of differentiated APIs and formulations to leading global pharma companies.
The pursuit of innovation and differentiation has given us a distinct competitive edge in the global marketplace.
Biocon has built state-of-the-art manufacturing facilities to develop cutting-edge biosimilars and ‘best-in-class’ differentiated small molecule APIs and formulations.
QUALITY & COMPLIANCE
At Biocon, excellence through Quality & Compliance is one of our core values and we strive to achieve it consistently across all functions.